Leading the Way in Life Science Technologies

GEN Exclusives

More »

Legal Affairs

More »
May 1, 2010 (Vol. 30, No. 9)

Patent Law Reform in the Works Again

Third Time Could Be the Charm for Legislative Efforts that Benefit Investors and Job Growth

  • Click Image To Enlarge +
    William L. Warren

    The most sweeping reform proposed for U.S. patent law in more than 55 years has made renewed progress through the legislative system. A Manager’s Amendment to the Bill for Patent Reform (S.515) was issued on March 4, 2010, from the Senate Judiciary Committee by Chairman Sen. Patrick Leahy (D-Vt.), former Chairman Sen. Orrin Hatch (R-Utah), and ranking member Sen. Jeff Sessions (R-Ala.).

    This is the third consecutive Congress in which Sens. Leahy and Hatch have presented patent-reform legislation in their stated effort to streamline the patent system to benefit inventors and to facilitate economic growth and jobs. 

    The compromise Senate Judiciary bill retains most of the provisions of the Patent Reform Act of 2009, including the transition to a first-inventor-to-file system. Significant modifications would affect patent prosecution, such as defining limitations on the inventor’s own prior art, establishing a procedure for supplemental examination, implementing a new inter partes patent review system, and extending patent fees-setting authority. Other revisions affecting patent litigation include a pretrial damages review, definition of the terms for willful infringement, limits on false marking claims, and interlocutory appeals.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »